MedTrace Logo

Ondansetron in the Prevention of Hypotension in Patients Undergoing Spinal Anesthesia

NCT03973411 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-06-04

No results posted yet for this study

Summary

Ondansetron, a potent 5-HT 3 receptor antagonist commonly used as an antiemetic. The main objective of the present study is to verify the hypothesis that blocking type 3 serotonin receptors with intravenous ondansetron reduces the incidence of spinal anesthesia-induced hypotension

Conditions

Interventions

DRUG

Prophylactic ondansetron

Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia

DRUG

Placebo

Pacients will receibe standard spinal anesthesia

Sponsors & Collaborators

  • Hospital de Base

    lead OTHER

Principal Investigators

  • Fabricio T Mendonça, MD · Hospital de Base do Distrito Federal

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03973411 on ClinicalTrials.gov